Home › Head and Neck Squamous Cell Carcinoma › Georgia › Atlanta
Head and Neck Squamous Cell Carcinoma clinical trials in Atlanta, GA
24 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in and around Atlanta (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RecruitingPhase 1
- Emory University, Atlanta
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
RecruitingPhase 3
- Emory University, Atlanta
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RecruitingPhase 2
- Emory University Hospital Midtown, Atlanta
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
RecruitingPhase 3
- Emory University Hospital Midtown, Atlanta
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
RecruitingPhase 1
- Emory University, Atlanta
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Emory Proton Therapy Center, Atlanta
- Emory University Hospital Midtown, Atlanta
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RecruitingPhase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RecruitingObservational study
- Morehouse, Atlanta
- Piedmont Healthcare, Atlanta
- Winship Cancer Institute, Emory University, Atlanta
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RecruitingPhase 2
- Emory University School of Medicine, Atlanta
Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
RecruitingPhase 2/3
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecruitingPhase 1/2
- Winship Cancer Institute - Emory University, Atlanta
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
RecruitingPhase 1/2
- Emory University, Atlanta
Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation
Recruiting
- Emory Midtown University Hospital/Winship Cancer Institute, Atlanta
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RecruitingPhase 1/2
- Winship Cancer Institute, Emory University, Atlanta
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- GSK Investigational Site, Atlanta
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
RecruitingPhase 2
- USA10-0, Atlanta
Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
Recruiting
- Emory University Hospital, Atlanta
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- Emory University, Atlanta
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 111, Atlanta
TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
RecruitingPhase 1
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
RecruitingPhase 2
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
RecruitingPhase 1/2
- Research Site 114, Atlanta
- Research Site 139, Atlanta
Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer
RecruitingEarly phase 1
- Emory University Hospital Midtown, Atlanta
A Beta-only IL-2 ImmunoTherapY Study
RecruitingPhase 1/2
- Emory - Winship Cancer Institute, Atlanta
Head and Neck Squamous Cell Carcinoma trials in other cities
- Houston, TX47 studies
- Los Angeles, CA42 studies
- Boston, MA40 studies
- New York City, NY39 studies
- Nashville, TN39 studies
- St. Louis, MO28 studies
- Arlington, VA26 studies
- Chicago, IL26 studies
- Philadelphia, PA26 studies
- San Antonio, TX22 studies
- New Haven, CT22 studies
- Pittsburgh, PA22 studies
Other studies in Atlanta
- Cancer (all types)49 studies
- Non-Small Cell Lung Cancer47 studies
- Multiple Myeloma42 studies
- Breast Cancer41 studies
- Prostate Cancer33 studies
- Acute Myeloid Leukemia31 studies
- Ovarian Cancer29 studies
- Colorectal Cancer29 studies
- Lung Cancer29 studies
- Metastatic Cancer28 studies
- Major Depressive Disorder25 studies
- Heart Failure25 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.